China-based startup Zhejiang Innoforce Pharmaceuticals Co., a contract development and manufacturing organisation (CDMO) dedicated to providing one-stop-shop services to Advanced Therapy Medicinal Product (ATMP) customers and partners, has announced Dr Dewan Zeng as the new Chief Executive Officer (CEO), effective immediately.

Dr Zeng is an internationally recognised pharmaceutical product and business development leader. She has successfully leveraged her technical insights and leadership skills to foster organisational growth in several previous companies.

Prior to joining Innoforce, Dr Zeng was Vice President, Global Head of Search and Evaluation, and Business Development at BeiGene, where she played a critical role in several transformative deals between BeiGene and other multi-national pharmaceutical companies. Dr Zeng was a global programme lead for over 20 clinical-stage assets at US biotech and international pharmaceutical companies (CV Therapeutics, Gilead, and Pfizer), where she was responsible for clinical and regulatory strategy and oversight of key clinical studies of those programmes. She supported IND submission for twenty investigational products and NDA approval of three innovative products in the US, Europe, and China.